MedTrace Logo

UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF

NCT05940545 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-10-05

No results posted yet for this study

Summary

UMIT-1: A Randomised Phase Ib Study to Determine the Phase II dose and to Evaluate the Safety and Efficacy of intravenous (IV) Favipiravir \& Ribavirin for the Treatment of CCHF

Conditions

  • CCHF

Interventions

DRUG

Favipiravir

Small molecule antiviral

DRUG

Ribavirin

Small molecule antiviral

Sponsors & Collaborators

  • Liverpool School of Tropical Medicine

    lead OTHER

Principal Investigators

  • Lucy E Read, PhD, MRCP · Liverpool School of Tropical Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-12
Primary Completion
2023-09-30
Completion
2023-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05940545 on ClinicalTrials.gov